RecruitMe Clinical Trial

HVTN 706: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals who Have Sex with Cis-gender Men and/or Transgender Individuals (Harlem Site).
The purpose of this study is to test a combination of vaccines against HIV. We want to see if the vaccines prevent people from getting HIV.
Sponsor:Janssen Vaccines & Prevention B.V.
Enrolling:Male and Female Patients
Study Length:30 Months
Clinic Visits:18
Age Range:Between 18 and 60 years old
IRB Number:AAAS6051
Contact: Jun Avelino Loquere: 212-305-2201 / HIV_studies@columbia.edu
Additional Study Information:

Almost 40,000 people get HIV in the U.S. each year and almost all infections occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year; however, we need other HIV prevention tools, including an effective HIV vaccine, to better protect people from HIV infection. An HIV vaccine is the best long-term hope for ending AIDS. We are looking for healthy men and transgender individuals, 18-60 years old, who are HIV-negative and at risk of acquiring HIV-1 infection to join our study. Not sure if you are eligible? Take the first step and request to be contacted by our study team. We'll follow up by asking you to complete a brief electronic prescreen questionnaire to find out if you meet basic study criteria. If you meet basic criteria, we'll invite you to our research site to review the study for which you may be eligible and possibly draw blood to find out if you meet additional medical criteria. You'll receive $50 for the screening visit. If you're eligible, consent to participate, and are assigned into the study vaccine or placebo, you will receive 4 vaccine injection visits during study for which you'll be compensated $100 for completing each injection visit. We'll also ask you to return to the research site another 14 times to complete follow up visits that require blood to be drawn for which you'll be compensated $50-75 for each visit. Your participation will help end HIV by informing medical science and HIV prevention efforts.

Do You Qualify?
Are you between 18 and 60 years old?YesNo
Are you HIV-negative?YesNo
Do you want to begin or continue a PrEP regimen?YesNo
Are you okay with having blood drawn?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Jun Avelino Loquere
Email: HIV_studies@columbia.edu
Phone: 212-305-2201